BRND NAME:- WESRAB-LS COMPOSITION: - Rabeprazole20mg+ Levosulpiride75mg (SR) Packing: - 10x10 (ALU-ALU) M.R.P:- 1650 Indications: • Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD). • Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) • Healing of Duodenal Ulcers • Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome. • Irritable bowel syndrome • Chronic Gastritis. Mechanism of Action: Rabeprazole belongs to a class of anti secretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. Levosulpiride is more selective and acts primarily as a dopamine D2 antagonist. Pharmacology: Pharmacodynamics: Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Levosulpiride acts as prokinetic agent. Rabeprazole: Absorption: Absolute bioavailability is approximately 52%. Route of Elimination: Following a single 20 mg oral dose of 14C-labeled rabeprazole, Approximately 90% of the Product was eliminated in the urine, primarily as thio-ether carboxylic acid; its lucuronide, and mercapturic acid metabolites. Levosulpiride: Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3hr. Route of Elimination: Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV).